Ignite Creation Date:
2024-05-06 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05738681
Status:
RECRUITING
Last Update Posted:
2023-02-22
First Post:
2022-07-11
Brief Title:
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury A Randomized Controlled Trial
Sponsor:
Mahidol University
Organization:
Mahidol University
Study Overview
Official Title:
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury A Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury AT-DILI
Detailed Description:
Tuberculosis is one of the most important infectious diseases and treatment related hepatitis from anti-TB drug was observed for 5-28 Slow acetylator status in the N-acetyltransferase 2 NAT2 genotype is a significant risk factor of anti-tuberculosis drug-induced liver injury AT-DILI We assessed the effect of N-acetylcysteine to prevent hepatitis from anti-TB drug in Thai population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None